查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1406796

生物同质激素市场 - 2018-2028 年全球产业规模、份额、趋势、机会和预测，按产品、荷尔蒙类型、最终用户、地区和竞争细分

Bioidentical Hormones Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Product, By Hormones Type, End User, By Region, and By Competition
出版日期: | 出版商: TechSci Research | 英文 178 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2022 年，全球生物同质激素市场价值为 35.4 亿美元，预计在预测期内将出现令人印象深刻的成长，到 2028 年，复合CAGR为5.35%。生物同质激素是合成激素，其结构与天然产生的荷尔蒙相同。人类的身体。这些荷尔蒙用于荷尔蒙替代疗法 (HRT)，以缓解荷尔蒙失衡的症状，尤其是更年期和停经后女性。

主要市场驱动因素

人口老化加剧

市场概况
预测期 2024-2028
2022 年市场规模 35.4亿美元
2028 年市场规模 48亿美元
2023-2028 年CAGR 5.35%
成长最快的细分市场 医院和诊所
最大的市场 北美洲

世界正在经历前所未有的人口结构变化，人口老化迅速加剧。随着年龄的增长，他们的身体会经历显着的荷尔蒙变化，特别是对于经历更年期的女性。这些变化通常会导致一系列令人痛苦的症状，因此，人们对生物同质激素作为潜在解决方案越来越感兴趣。

目录

第 1 章：产品概述

  • 市场定义
  • 市场范围
    • 涵盖的市场
    • 考虑学习的年份
    • 主要市场区隔

第 2 章：研究方法

  • 研究目的
  • 基线方法
  • 主要产业伙伴
  • 主要协会和二手资料来源
  • 预测方法
  • 数据三角测量与验证
  • 假设和限制

第 3 章：执行摘要

  • 市场概况
  • 主要市场细分概述
  • 主要市场参与者概述
  • 重点地区/国家概况
  • 市场驱动因素、挑战、趋势概述

第 4 章：客户之声

第 5 章：全球生物同质荷尔蒙市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 副产品（乳霜和凝胶、注射、贴片和植入物、片剂和胶囊）
    • 依激素类型（雌激素、黄体酮、睪固酮）
    • 按最终用户（学术和研究机构、医院和诊所、其他）
    • 按地区
    • 按公司划分 (2022)
  • 产品市场地图
    • 按产品分类
    • 依激素类型
    • 按最终用户
    • 按地区

第 6 章：北美生物同质荷尔蒙市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 副产品（乳霜和凝胶、注射、贴片和植入物、片剂和胶囊）
    • 依激素类型（雌激素、黄体酮、睪固酮）
    • 按最终用户（学术和研究机构、医院和诊所、其他）
    • 按国家/地区
  • 北美：国家分析
    • 美国
    • 加拿大
    • 墨西哥

第 7 章：欧洲生物同质荷尔蒙市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 副产品（乳霜和凝胶、注射、贴片和植入物、片剂和胶囊）
    • 依激素类型（雌激素、黄体酮、睪固酮）
    • 按最终用户（学术和研究机构、医院和诊所、其他）
    • 按国家/地区
  • 欧洲：国家分析
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙

第 8 章：亚太地区生物同质荷尔蒙市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 副产品（乳霜和凝胶、注射、贴片和植入物、片剂和胶囊）
    • 依激素类型（雌激素、黄体酮、睪固酮）
    • 按最终用户（学术和研究机构、医院和诊所、其他）
    • 按国家/地区
  • 亚太地区：国家分析
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国

第 9 章：南美洲生物同质荷尔蒙市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 副产品（乳霜和凝胶、注射、贴片和植入物、片剂和胶囊）
    • 依激素类型（雌激素、黄体酮、睪固酮）
    • 按最终用户（学术和研究机构、医院和诊所、其他）
    • 按国家/地区
  • 南美洲：国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第 10 章：中东和非洲生物同质荷尔蒙市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 副产品（乳霜和凝胶、注射、贴片和植入物、片剂和胶囊）
    • 依激素类型（雌激素、黄体酮、睪固酮）
    • 按最终用户（学术和研究机构、医院和诊所、其他）
    • 按国家/地区
  • MEA：国家分析
    • 南非生物同质激素
    • 沙乌地阿拉伯生物同质激素
    • 阿联酋生物同质激素
    • 科威特生物同质激素

第 11 章：市场动态

  • 司机
  • 挑战

第 12 章：市场趋势与发展

  • 近期发展
  • 併购
  • 产品发布

第 13 章：波特的五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的力量
  • 客户的力量
  • 替代产品的威胁

第14章：竞争格局

  • 商业概览
  • 产品供应
  • 最近的发展
  • 财务（据报导）
  • 主要人员
  • SWOT分析
    • Merck KGaA
    • Pfizer Inc
    • Noven Pharmaceuticals Inc
    • SottoPelle
    • BioTE Medical, LLC
    • Bayer AG
    • Novo Nordisk A/S
    • TherapeuticsMD Inc
    • Novartis AG
    • Orion Pharma A/S

第 15 章：策略建议

第 16 章：关于我们与免责声明

简介目录
Product Code: 19535

Global Bioidentical Hormones Market has valued at USD 3.54 billion in 2022 and is anticipated to project impressive growth in the forecast period with a CAGR of 5.35% through 2028. Bioidentical hormones are synthetic hormones that are designed to be structurally identical to the hormones naturally produced in the human body. These hormones are used in hormone replacement therapy (HRT) to alleviate symptoms of hormonal imbalances, particularly in menopausal and postmenopausal women.

Key Market Drivers

Increasing Aging Population

Market Overview
Forecast Period2024-2028
Market Size 2022USD 3.54 Billion
Market Size 2028USD 4.80 Billion
CAGR 2023-20285.35%
Fastest Growing SegmentHospitals & Clinics
Largest MarketNorth America

The world is witnessing an unprecedented demographic shift with a rapidly increasing aging population. As people age, their bodies undergo significant hormonal changes, particularly in women experiencing menopause. These changes often lead to a range of distressing symptoms, and as a result, there has been a growing interest in bioidentical hormones as a potential solution.

The aging population is a global phenomenon. With advancements in healthcare and improvements in living conditions, people are living longer than ever before. As a result, the number of individuals entering the age group where hormonal imbalances and related symptoms become prevalent is increasing significantly.

As individuals age, they often seek ways to alleviate the uncomfortable symptoms associated with hormonal imbalances. Hot flashes, mood swings, reduced bone density, and sleep disturbances are common issues experienced during menopause. This rising demand for relief has spurred interest in hormone replacement therapy.

Many aging individuals are now showing a preference for bioidentical hormones over traditional synthetic hormone replacement therapy. Bioidentical hormones are designed to mimic the body's natural hormones closely, which is appealing to those who prefer a more natural and potentially safer approach to HRT.

Bioidentical hormones offer a high degree of personalization. Healthcare providers can tailor treatment plans to address an individual's specific hormone imbalances and symptoms. This personalized approach resonates with aging individuals who seek treatments that are more aligned with their unique needs.

As the aging population becomes more informed and proactive about their health, they are increasingly aware of the benefits of bioidentical hormones. Patients are more likely to engage in discussions with their healthcare providers about these treatment options.

Advances in healthcare and medical research have resulted in a deeper understanding of the benefits and safety of bioidentical hormones. This knowledge has contributed to greater acceptance and trust in these therapies among both patients and healthcare providers.

Rising Awareness and Education

In today's information age, knowledge is power, especially when it comes to healthcare decisions. The global bioidentical hormones market has been experiencing a notable surge, and a significant driver behind this growth is the rising awareness and education about the benefits of bioidentical hormones.

Awareness begins with understanding. As people become more informed about what bioidentical hormones are and how they differ from synthetic counterparts, they are better equipped to make educated decisions about their healthcare.

Patients and healthcare providers are increasingly recognizing that bioidentical hormones are designed to mimic the body's natural hormones closely. This differentiation from synthetic hormones underscores the appeal of a more natural and potentially safer approach to hormone replacement therapy (HRT).

A well-informed public is less susceptible to myths and misconceptions surrounding bioidentical hormones. Accurate education helps dispel fears and uncertainties, allowing individuals to make choices based on facts rather than hearsay.

The internet has democratized access to medical information. Patients can now access a wealth of resources online, including reputable medical websites, peer-reviewed research, and patient testimonials. This information empowers individuals to engage in informed discussions with their healthcare providers.

Healthcare professionals play a critical role in disseminating information about bioidentical hormones. As they become more educated about the benefits and safety of these therapies, they can offer informed guidance to patients considering HRT.

Patient advocacy groups and organizations focused on women's health and hormonal issues have also contributed to raising awareness. They provide a platform for sharing experiences, information, and support, further empowering individuals to explore bioidentical hormone therapies.

High-profile individuals and celebrities who openly discuss their experiences with bioidentical hormones have also contributed to raising awareness. Their stories can inspire others to explore these treatment options.

Ongoing clinical studies and research on bioidentical hormones have provided data supporting their safety and efficacy. This scientific backing is vital in reassuring both patients and healthcare providers about the benefits of these therapies.

Patient Preference for Natural Alternatives

In today's healthcare landscape, an increasing number of patients are seeking out natural and holistic alternatives to address their medical concerns. This shift in patient preferences is significantly boosting the growth of the global bioidentical hormones market. Bioidentical hormones, often considered a more natural and individualized approach to hormone therapy, have gained substantial popularity.

Patients worldwide are becoming more conscious of their health and well-being. This increased awareness extends to a preference for treatments and therapies that align with natural, holistic, and organic principles.

Bioidentical hormones are synthesized to closely resemble the body's natural hormones. This "mimicking nature" aspect is particularly appealing to patients who are drawn to treatments that work in harmony with the body's own processes.

Many individuals are wary of synthetic hormones, fearing potential side effects and risks. Bioidentical hormones, being derived from natural sources and designed to match the body's hormones, are seen as a safer and less intrusive option.

Patient preference for natural alternatives extends to personalized healthcare. Bioidentical hormone therapy allows for tailored treatment plans, addressing an individual's unique hormonal imbalances and symptoms. Patients appreciate this personalized approach over one-size-fits-all solutions.

The holistic health movement emphasizes the interconnectedness of physical, emotional, and mental well-being. Bioidentical hormone therapy fits well within this framework, as it aims to restore hormonal balance, potentially impacting various aspects of health and quality of life.

Advocacy groups and healthcare practitioners focused on natural and integrative medicine have been instrumental in promoting bioidentical hormones as a viable treatment option. Their support has contributed to heightened patient interest.

In an era of patient-centered care, individuals are actively involved in their healthcare decisions. Patients are more likely to seek out and request treatments they believe align with their values and preferences, including those perceived as more natural.

Expanding Product Portfolio

The global bioidentical hormones market is experiencing remarkable growth, driven in part by the diversification and expansion of product offerings. As the market evolves, pharmaceutical companies and compounding pharmacies are continuously innovating and broadening their product portfolios to meet the diverse needs and preferences of patients and healthcare providers.

One of the most significant advantages of an expanding product portfolio is the ability to cater to a wide range of patients' needs. Different patients may have varying preferences when it comes to the form and method of hormone administration. A diverse product portfolio offers choices such as creams, gels, patches, oral tablets, and more, ensuring that patients can select the option that best suits their comfort and lifestyle.

Bioidentical hormone therapy is renowned for its personalized approach to treatment. An expanded product portfolio allows healthcare providers to fine-tune therapy plans, selecting the specific formulation and delivery method that aligns with each patient's unique hormonal imbalances and symptoms. This level of customization is a significant factor in patient satisfaction and treatment success.

Different regions and countries may have specific regulations and guidelines governing the production and distribution of bioidentical hormones. An expanded product portfolio enables manufacturers to adapt to various regulatory requirements, facilitating broader market access and compliance.

The competitive nature of the bioidentical hormones market spurs companies to invest in research and development (R&D) to create new and improved formulations. These innovations can lead to safer, more effective, and more convenient products, further increasing the appeal of bioidentical hormones.

Some patients may require a combination of hormones to address their specific hormonal imbalances comprehensively. An expanded product portfolio allows providers to offer combination therapies, ensuring that patients receive holistic treatment that targets all their needs.

The availability of a broader range of bioidentical hormone products enhances accessibility for patients. They can more easily find the products that align with their treatment preferences and therapeutic requirements.

Key Market Challenges

Regulatory Complexity

The regulatory landscape for bioidentical hormones varies widely from one country to another. In some regions, these hormones are classified as pharmaceuticals and subject to stringent regulatory oversight. In contrast, in other areas, they may be categorized as dietary supplements, leading to less regulation. This disparity in regulatory standards can create confusion for manufacturers, healthcare providers, and patients alike.

Lack of Large-Scale Clinical Trials

The bioidentical hormones market often relies on smaller-scale clinical studies and patient testimonials to demonstrate efficacy. The absence of large-scale, long-term clinical trials can hinder broader acceptance of these therapies among healthcare providers and regulatory bodies, who typically prefer robust scientific evidence.

Accessibility and Availability

The availability of bioidentical hormone therapies can be limited in certain regions, especially in countries with stricter regulations or were compounded medications face challenges in distribution and accessibility. Patients in these areas may have difficulty accessing these treatments.

Key Market Trends

Increasing Demand for Personalized Hormone Therapies

Personalization is the buzzword in healthcare, and the bioidentical hormones market is no exception. Patients are seeking tailored treatment plans that address their specific hormonal imbalances and symptoms. The market is expected to witness a surge in demand for customized hormone therapies to meet this growing preference.

Advanced Formulations and Delivery Methods

Innovation in formulations and delivery methods will be a key trend. Companies are likely to invest in research and development to create more effective, convenient, and patient-friendly bioidentical hormone products. This includes novel delivery mechanisms such as subcutaneous implants and long-acting injections.

Focus on Men's Hormonal Health

While bioidentical hormones have traditionally been associated with women's health, there is a growing recognition of their potential benefits for men as well. Hormonal imbalances in men can lead to issues such as low testosterone levels, and bioidentical hormone therapies may become more widely adopted in this demographic.

Segmental Insights

Hormones Type Insights

Based on the category of Hormones Type, Estrogens are poised to dominate the Global Bioidentical Hormones Market in 2022 due to a combination of factors. Firstly, the rising awareness and demand for hormone replacement therapies among aging populations, particularly women, is a key driver. Estrogens play a crucial role in addressing various menopausal symptoms, including hot flashes, mood swings, and osteoporosis. Additionally, the increasing prevalence of hormonal imbalances and related health issues has led to a growing need for personalized, bioidentical hormone therapies. Estrogens, being one of the primary female sex hormones, are at the forefront of this demand. Moreover, advancements in biotechnology and the development of innovative delivery methods have made bioidentical estrogen treatments more accessible and effective, further solidifying their dominance in the global market. As healthcare continues to prioritize patient-specific solutions, the dominance of estrogens in the bioidentical hormones market is expected to persist and expand in the coming years.

Product Insights

Tablets and capsules are poised to dominate the Global Bioidentical Hormones Market in 2022 for several compelling reasons. Firstly, these oral dosage forms offer convenience and ease of administration, making them a preferred choice for both patients and healthcare providers. Their portability and simplicity in dosing ensure widespread patient compliance, a critical factor in hormone therapy. Secondly, tablets and capsules allow for precise dosing, ensuring that patients receive the right number of bioidentical hormones consistently. This accuracy is crucial in hormone replacement therapy to achieve desired clinical outcomes and minimize potential side effects. Additionally, tablets and capsules can be manufactured with extended-release formulations, providing a sustained therapeutic effect, which is particularly advantageous in hormone therapy. Furthermore, the pharmaceutical industry's continuous advancements in tablet and capsule formulations, including improved bioavailability and taste-masking technologies, enhance their market dominance. As the demand for bioidentical hormones continues to rise globally, tablets and capsules are well-positioned to maintain their stronghold in meeting the diverse needs of patients and healthcare providers.

Regional Insights

North America is poised to dominate the Global Bioidentical Hormones Market in 2022 for several compelling reasons. Firstly, the region benefits from a well-established healthcare infrastructure and a robust pharmaceutical industry that is at the forefront of research and development in hormone therapies. This translates into a wide range of bioidentical hormone products and treatment options readily available to patients and healthcare providers. Secondly, the increasing aging population in North America, along with a growing awareness of the benefits of bioidentical hormones for managing menopausal and age-related health concerns, drives the demand for such therapies. Moreover, the region's stringent regulatory framework ensures product safety and efficacy, instilling confidence among both patients and healthcare professionals. Additionally, a strong emphasis on patient education and personalized medicine in North America further boosts the market, as individuals seek tailored hormone replacement solutions. These factors collectively position North America to maintain its dominance in the Global Bioidentical Hormones Market for the foreseeable future.

Key Market Players

Merck KGaA

Pfizer Inc

Noven Pharmaceuticals Inc

SottoPelle

BioTE Medical, LLC

Bayer AG

Novo Nordisk A/S

TherapeuticsMD Inc

Novartis AG

Orion Pharma A/S

Report Scope:

In this report, the Global Bioidentical Hormones Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Bioidentical Hormones Market, By Product:

  • Creams & Gels
  • Injectable
  • Patches & Implants, Tablets & Capsules

Bioidentical Hormones Market, By Hormones Type:

  • Estrogens
  • Progesterone
  • Testosterone

Bioidentical Hormones Market, By End User:

  • Academic & Research Institutes
  • Hospitals & Clinics
  • Others

Bioidentical Hormones Market, By Region:

  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • Germany
  • United Kingdom
  • France
  • Italy
  • Spain
  • Asia-Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in the Global Bioidentical Hormones Market.

Available Customizations:

  • Global Bioidentical Hormones market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Bioidentical Hormones Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Creams & Gels, Injectable, Patches & Implants, Tablets & Capsules)
    • 5.2.2. By Hormones Type (Estrogens, Progesterone, Testosterone)
    • 5.2.3. By End User (Academic & Research Institutes, Hospitals & Clinics, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2022)
  • 5.3. Product Market Map
    • 5.3.1. By Product
    • 5.3.2. By Hormones Type
    • 5.3.3. By End User
    • 5.3.4. By Region

6. North America Bioidentical Hormones Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product (Creams & Gels, Injectable, Patches & Implants, Tablets & Capsules)
    • 6.2.2. By Hormones Type (Estrogens, Progesterone, Testosterone)
    • 6.2.3. By End User (Academic & Research Institutes, Hospitals & Clinics, Others)
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Bioidentical Hormones Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By Hormones Type
        • 6.3.1.2.3. By End User
    • 6.3.2. Canada Bioidentical Hormones Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By Hormones Type
        • 6.3.2.2.3. By End User
    • 6.3.3. Mexico Bioidentical Hormones Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By Hormones Type
        • 6.3.3.2.3. By End User

7. Europe Bioidentical Hormones Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product (Creams & Gels, Injectable, Patches & Implants, Tablets & Capsules)
    • 7.2.2. By Hormones Type (Estrogens, Progesterone, Testosterone)
    • 7.2.3. By End User (Academic & Research Institutes, Hospitals & Clinics, Others)
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Bioidentical Hormones Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By Hormones Type
        • 7.3.1.2.3. By End User
    • 7.3.2. United Kingdom Bioidentical Hormones Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By Hormones Type
        • 7.3.2.2.3. By End User
    • 7.3.3. France Bioidentical Hormones Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By Hormones Type
        • 7.3.3.2.3. By End User
    • 7.3.4. Italy Bioidentical Hormones Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By Hormones Type
        • 7.3.4.2.3. By End User
    • 7.3.5. Spain Bioidentical Hormones Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By Hormones Type
        • 7.3.5.2.3. By End User

8. Asia-Pacific Bioidentical Hormones Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product (Creams & Gels, Injectable, Patches & Implants, Tablets & Capsules)
    • 8.2.2. By Hormones Type (Estrogens, Progesterone, Testosterone)
    • 8.2.3. By End User (Academic & Research Institutes, Hospitals & Clinics, Others)
    • 8.2.4. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Bioidentical Hormones Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By Hormones Type
        • 8.3.1.2.3. By End User
    • 8.3.2. Japan Bioidentical Hormones Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By Hormones Type
        • 8.3.2.2.3. By End User
    • 8.3.3. India Bioidentical Hormones Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By Hormones Type
        • 8.3.3.2.3. By End User
    • 8.3.4. Australia Bioidentical Hormones Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By Hormones Type
        • 8.3.4.2.3. By End User
    • 8.3.5. South Korea Bioidentical Hormones Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By Hormones Type
        • 8.3.5.2.3. By End User

9. South America Bioidentical Hormones Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product (Creams & Gels, Injectable, Patches & Implants, Tablets & Capsules)
    • 9.2.2. By Hormones Type (Estrogens, Progesterone, Testosterone)
    • 9.2.3. By End User (Academic & Research Institutes, Hospitals & Clinics, Others)
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Bioidentical Hormones Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By Hormones Type
        • 9.3.1.2.3. By End User
    • 9.3.2. Argentina Bioidentical Hormones Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By Hormones Type
        • 9.3.2.2.3. By End User
    • 9.3.3. Colombia Bioidentical Hormones Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By Hormones Type
        • 9.3.3.2.3. By End User

10. Middle East and Africa Bioidentical Hormones Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product (Creams & Gels, Injectable, Patches & Implants, Tablets & Capsules)
    • 10.2.2. By Hormones Type (Estrogens, Progesterone, Testosterone)
    • 10.2.3. By End User (Academic & Research Institutes, Hospitals & Clinics, Others)
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Bioidentical Hormones Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By Hormones Type
        • 10.3.1.2.3. By End User
    • 10.3.2. Saudi Arabia Bioidentical Hormones Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By Hormones Type
        • 10.3.2.2.3. By End User
    • 10.3.3. UAE Bioidentical Hormones Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By Hormones Type
        • 10.3.3.2.3. By End User
    • 10.3.4. Kuwait Bioidentical Hormones Market Outlook
      • 10.3.4.1. Market Size & Forecast
        • 10.3.4.1.1. By Value
      • 10.3.4.2. Market Share & Forecast
        • 10.3.4.2.1. By Product
        • 10.3.4.2.2. By Hormones Type
        • 10.3.4.2.3. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Development
  • 12.2. Mergers & Acquisitions
  • 12.3. Product Launches

13. Porter's Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Products

14. Competitive Landscape

  • 14.1. Business Overview
  • 14.2. Product Offerings
  • 14.3. Recent Developments
  • 14.4. Financials (As Reported)
  • 14.5. Key Personnel
  • 14.6. SWOT Analysis
    • 14.6.1. Merck KGaA
    • 14.6.2. Pfizer Inc
    • 14.6.3. Noven Pharmaceuticals Inc
    • 14.6.4. SottoPelle
    • 14.6.5. BioTE Medical, LLC
    • 14.6.6. Bayer AG
    • 14.6.7. Novo Nordisk A/S
    • 14.6.8. TherapeuticsMD Inc
    • 14.6.9. Novartis AG
    • 14.6.10. Orion Pharma A/S

15. Strategic Recommendations

16. About Us & Disclaimer